NCT06763965 2026-03-23
Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Phase 1/2 Enrolling by invitation
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Shandong Cancer Hospital and Institute
Siriraj Hospital